- Home
- OGG vs BBNX Comparison
OGG vs BBNX Comparison
Compare OGG & BBNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | OGG | BBNX |
|---|---|---|
| Founded | N/A | 2015 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | | Medical/Dental Instruments |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 871.6M | 997.9M |
| IPO Year | 2008 | 2025 |
Fundamental Metrics
Financial Performance| Metric | OGG | BBNX |
|---|---|---|
| Price | $2.84 | $17.62 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 14 |
| Target Price | N/A | ★ $23.80 |
| AVG Volume (30 Days) | ★ 1.4M | 1.4M |
| Earning Date | 11-09-2026 | 10-27-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 78.95 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $100,251,000.00 |
| Revenue This Year | N/A | $25.74 |
| Revenue Next Year | N/A | $44.51 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 53.94 |
| 52 Week Low | $2.22 | $8.80 |
| 52 Week High | $3.30 | $32.71 |
Technical Indicators
Market Signals| Indicator | OGG | BBNX |
|---|---|---|
| Relative Strength Index (RSI) | 54.53 | 37.29 |
| Support Level | $2.84 | $15.76 |
| Resistance Level | $2.93 | $18.20 |
| Average True Range (ATR) | 0.11 | 1.08 |
| MACD | 0.00 | -0.46 |
| Stochastic Oscillator | 64.47 | 4.62 |
Price Performance
Historical ComparisonAbout OGG Osisko Gold Group Inc. Common Shares
Osisko Gold Group Inc is a continental North American gold development company focused on past producing mining camps with district-scale potential. The company's objective is to become an intermediate gold producer through the development of its flagship, Cariboo Gold Project, located in central British Columbia, Canada. Its project portfolio also includes the Tintic Project in the East Tintic mining district of Utah, United States.
About BBNX Beta Bionics Inc.
Beta Bionics Inc is a commercial-stage medical device company engaged in the design, development, and commercialization of solutions to improve the health and quality of life of insulin-requiring people with diabetes (PWD) by utilizing adaptive closed-loop algorithms to simplify and improve the treatment of their disease. The company's product includes the iLet Bionic Pancreas (iLet). The company operates as a single segment, focused on the development, manufacture, and sale of the iLet.